A new HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 in over 100 low- and middle-income countries by 2027, potentially transforming HIV prevention efforts worldwide and helping to curb the epidemic.
The first over-the-counter birth control pill in the US, Opill, has been shipped to major retailers and pharmacies, with a one-month supply costing $19.99 and a three-month supply priced at $49.99. Opill will also be available online and through select retailers, offering a six-month supply for $89.99. While it is 98% effective at preventing pregnancy when taken as directed, concerns about cost and accessibility persist, with advocacy groups urging for lower pricing. Perrigo has announced a cost assistance program for qualified low-income and uninsured individuals, and the pill may be eligible for payment or reimbursement through insurance accounts. Despite potential barriers, healthcare professionals view Opill as a positive step toward improving access to high-quality birth control.